NEXCEDE
LOE ApproachingNDAORALFILM
Approved
Nov 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEXCEDE is an oral film formulation approved by Novartis in 2009 as a small-molecule NDA. The specific indication and mechanism of action are not publicly detailed in available data, limiting assessment of therapeutic positioning.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting contraction of brand team and focus on generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NEXCEDE currently shows zero linked job openings, reflecting its mature LOE-approaching lifecycle stage. Career opportunities are likely concentrated in defense strategies, generic preparation, and portfolio transition planning rather than growth-focused roles.
Brand ManagerProduct Manager
Worked on NEXCEDE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.